Alkermes announced early clinical data indicating that its investigational orexin agonist, ALKS 7290, may have therapeutic activity in adults with attention-deficit/hyperactivity disorder (ADHD). Orexin agonists are a drug class that has been previously developed for rare sleep disorders; this report represents the company’s first public claim that the class could be beneficial in ADHD.
The company described findings from a randomized Phase 1 study in which ALKS 7290 was reportedly well tolerated and produced a measurable reduction in ADHD symptoms over a short treatment period.
Alkermes characterized the trial as a randomized Phase 1 study. Participants enrolled in the study had notable symptom burden at baseline: the median score on the Adult ADHD Investigator Symptom Rating Scale was 39, a level the company interprets as reflecting moderate to severe symptoms.
The public summary specified a high dose of 50 milligrams for one treatment arm. Beyond randomization and the 50 mg high-dose group, the publicly available article did not provide additional operational details such as total sample size, the number of treatment arms, use of placebo or active comparator, inclusion/exclusion criteria, or demographic characteristics of participants.
Alkermes reported that after two weeks of treatment, participants receiving the high dose of 50 mg ALKS 7290 experienced a 19-point reduction on the Adult ADHD Investigator Symptom Rating Scale. The company described this magnitude of change as a shift in symptom severity from moderate–severe to mild.
The statement frames this result as an early signal of efficacy in a study primarily designed for early clinical assessment. The public summary did not include detailed efficacy data such as response rates, confidence intervals, p values, effect sizes beyond the median change, or subgroup analyses. Longer-term outcomes beyond the two-week window were not reported in the article.
Alkermes reported that ALKS 7290 was "well tolerated" in the Phase 1 study. The public summary provided no granular safety data in the text cited, such as rates or types of adverse events, serious adverse events, discontinuations, laboratory changes, or vital sign data. Detailed tolerability and safety analyses were not available in the summary referenced by the source article.
The STAT News summary is brief and the full story on the site was accessible only to subscribers at the time of capture. As reported publicly by Alkermes and relayed in the article, several important methodological and outcome details were not disclosed in the summary:
Because these items were not reported in the public summary, they cannot be verified from the source alone.
The company’s announcement positions ALKS 7290 as an early candidate for ADHD treatment and suggests that orexin agonists could represent a novel mechanism of action in this indication. Given the Phase 1 setting and the limited public data, the findings should be regarded as preliminary. Confirmation in larger, controlled Phase 2 and Phase 3 trials with transparent reporting of sample sizes, statistical analyses, safety outcomes, and longer follow-up will be required to determine whether ALKS 7290 can offer a meaningful clinical benefit for adults with ADHD.
The public summary highlights an initial efficacy signal and tolerability over two weeks at 50 mg, but many details necessary for full clinical interpretation were not reported in the source article. Clinicians and researchers should await full data releases or peer-reviewed publication for complete evaluation of the compound’s risk–benefit profile.